TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study.

  title={TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study.},
  author={Edward Lewis Tobinick and Hyman Gross and Alan M. Weinberger and Hart Cohen},
  journal={MedGenMed : Medscape general medicine},
  volume={8 2},
CONTEXT Current pharmacologic treatments for Alzheimer's disease (AD) do not prevent long-term clinical deterioration. Tumor necrosis factor (TNF)-alpha, a proinflammatory cytokine, has been implicated in the pathogenesis of AD. OBJECTIVE To investigate the use of a biologic TNF-alpha inhibitor, etanercept was given by perispinal extrathecal administration for the treatment of AD. METHODS This was a prospective, single-center, open-label, pilot (proof-of-concept) study, in which 15 patients… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 106 extracted citations


Publications referenced by this paper.
Showing 1-10 of 57 references

Clinical aspects of inflammation in Alzheimer's disease

  • PB Rosenberg
  • Int Rev Psychiatry
  • 2005

Similar Papers

Loading similar papers…